A popular asthma inhaler will be discontinued in January. Here's what to know.
CBSN
Flovent, a popular steroid inhaler used to treat and control asthma symptoms in children and adults, is being discontinued next week as its manufacturer prepares to roll out a generic version of the medication.
Starting on Jan. 1, 2024, GlaxoSmithKline will stop manufacturing Flovent HFA and Flovent Diskus. In its place, the biopharmaceutical company will produce a generic version of the prescription inhaler featuring an identical formula and drug-delivery mechanism, GSK said in a statement last fall posted by the Allergy Foundation of America (AAFA).
While GSK says Flovent's generic makeover will "provide patients in the U.S. with potentially lower cost alternatives of ... medically important products," some medical professionals aren't convinced. According to some experts, the switch-up could negatively impact patients' pocketbooks and their health.
President Biden on Monday signed into law a defense bill that authorizes significant pay raises for junior enlisted service members, aims to counter China's growing power and boosts overall military spending to $895 billion despite his objections to language stripping coverage of transgender medical treatments for children in military families.
It's Christmas Eve, and Santa Claus is suiting up for his annual voyage from the North Pole to households around the world. In keeping with decades of tradition, the North American Aerospace Command, or NORAD, will once again track Santa's journey to deliver gifts to children before Christmas 2024, using an official map that's updated consistently to show where he is right now.
An anti-money laundering law called the Corporate Transparency Act, or CTA, appears to have been given new life after an appeals court on Monday determined its rules can be enforced as the case proceeds. The law requires small business owners to register with the Financial Crimes Enforcement Network, or FinCEN, by Jan. 1, or potentially pay fines of up to $10,000.